Lessons learned from marketed and investigational prodrugs.
Ettmayer
Peter
P
Novartis Institute for BioMedical Research, Brunnerstrasse 59, A-1235 Vienna, Austria. peter.ettmayer@pharma.novartis.com
Amidon
Gordon L
GL
Clement
Bernd
B
Testa
Bernard
B
D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D001682:Biological Availability; D001692:Biological Transport; D002352:Carrier Proteins / Q000378:metabolism; D004337:Drug Carriers; D016503:Drug Delivery Systems; D015195:Drug Design; D015507:Drugs, Investigational / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D006801:Humans; D007408:Intestinal Absorption; D011355:Prodrugs / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D012995:Solubility
D000970:Antineoplastic Agents; D002352:Carrier Proteins; D004337:Drug Carriers; D015507:Drugs, Investigational; D011355:Prodrugs